Answers are grounded in this paper and cite their sources.
Case report illustrates SMARCA4-deficient non-small cell lung cancer diagnosis and treatment options, highlighting a unique EGFR mutation.
SWI/SNF‑related, matrix‑associated, actin‑dependent regulator of chromatin, subfamily a, member 4 (SMARCA4)‑deficient non‑small cell lung cancer (dNSCLC) is a rare malignant tumor that originates in the lungs. It occurs more frequently in male smokers, and the epidermal growth factor receptor (EGFR) gene is often mutation‑free. In the present study, the case of a 60‑year‑old, non‑smoking female patient diagnosed with SMARCA4‑dNSCLC is reported. Biopsy of the tumor showed solid flaky, nest‑like infiltrating growth. Immunohistochemistry revealed the following: SMARCA4/BRG1(‑), SMARCB1/INI‑1(+), cytokeratin7 (+), cytokeratin 5.2 (+), CK5/6(+) and calretinin(+). The Ki‑67 positivity index was 75%, and the thyroid transcription factor‑1, NapsinA, p40, nuclear protein in testis, CD34, Sal‑like protein 4, SRY‑box transcription factor 2 and synaptophysin were negative. Molecular analysis showed mutations in both EGFR and TP53. The pathological diagnosis was SMARCA4‑dNSCLC with an EGFR gene mutation. The present case report could be used for broadening the pathological diagnosis of SMARCA4‑dNSCLC and for selecting appropriate treatment approaches.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: